ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Clinical Practice Session

Novel Treatments for Resistant Hypertension in Advanced CKD

November 03, 2022 | 02:00 PM - 04:00 PM

Location: W311, Orange County Convention Center‚ West Building

Session Description

Resistant hypertension is a major contributor to the excess morbidity and mortality in patients with advanced CKD. This session presents novel agents and device therapy for the treatment of resistant hypertension. Particular emphasis is given to the nonsteroidal mineralocorticoid receptor blocker (KBP-5074), combined endothelin A and B antagonists, and centrally acting aminopeptidase inhibitors. In addition, updates are given on the use of kidney denervation.

Learning Objective(s)

  • Implement the use of a novel nonsteroidal mineralocorticoid receptor blocker (KBP-5074) in patients with advanced CKD and resistant hypertension
  • Explain the rationale for using combined endothelin A and B receptor antagonists for the treatment of resistant hypertension in patients with advanced CKD
  • Describe the use of centrally acting aminopeptidase inhibitors for the treatment of resistant hypertension in Black patients with CKD
  • Summarize the current state of kidney denervation therapy as a treatment modality for patients with CKD and resistant hypertension

Learning Pathway(s)

  • Hypertension and Cardiorenal Disorders


  • George L. Bakris, MD, FASN
  • Karen A. Griffin, MD, FASN